Ardena makes T3S trial drug for Cardiff University's LIONNS-D2 Project
- Cardiff University
- Wales
- Direct
- 6 November 2025 to 31 January 2027
Cardiff University chose Ardena Holding NV to make T3S (triiodothyronine sulphate), a new drug, for a Phase 2b clinical trial.
The work is for the LIONNS-D2 Project in the university's School of Medicine. The drug is meant for hypothyroid patients whose particular genetic variant changes how their bodies process thyroid hormone. Ardena produces the finished doses in blister packs as well as the trial medicine and its active ingredient, all to GMP standards. The drug's synthesis route is already validated, with preclinical and toxicology data behind it.
The contract was awarded directly and runs from November 2025 to January 2027. No value was published.
Contract ends January 2027
- What
- Aseptic compounding, specials and contract pharmaceutical manufacturing
- Buyer
- Cardiff University
- Supplier
- Ardena Holding NV
- Value
- Not published
- How it was bought
- Direct
- Dates and next
- Nov 2025 to Jan 2027